Glucotrack Seeks Shareholder Approval for Highly Dilutive Capital Raises Critical for Survival

summarizeSummary

Glucotrack, Inc. filed a preliminary proxy statement to seek shareholder approval for two highly dilutive capital raises, including an Equity Line of Credit and warrant exercises, which are crucial for the company's survival but will significantly dilute existing shareholders.

check_boxKey Events

• Shareholder Vote on $20M Equity Line of Credit

  The company is seeking approval to issue shares under a September 2025 agreement with Sixth Borough Capital Fund, LP, for up to $20.0 million. This requires shareholder consent as it could exceed 20% dilution, representing a substantial capital raise relative to the company's market cap.

• Approval for Highly Dilutive Warrant Exercise

  Shareholders will vote on the issuance of shares from the exercise of 2,067,182 common warrants from a December 2025 private placement. This could generate approximately $8 million but would result in the investor owning about 77% of the company's post-issuance common stock, with the company warning of potential liquidation if not approved.

• Auditor Ratification

  The filing also includes a proposal to ratify the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for 2025, following the dismissal of Grant Thornton in July 2025, which had previously noted going concern issues.

auto_awesomeAnalysis

Glucotrack, Inc. is seeking shareholder approval for two highly dilutive capital-raising initiatives that are critical for the company's continued operations. The first proposal involves an Equity Line of Credit (ELOC) with Sixth Borough Capital Fund, LP, allowing the company to sell up to $20.0 million in common stock. This amount is nearly ten times the company's current market capitalization and requires shareholder approval due to potential dilution exceeding 20% of outstanding shares. The second proposal seeks approval for the issuance of shares upon the exercise of over 2 million common warrants from a private placement that closed on December 31, 2025. This could bring in approximately $8 million but would result in the investor owning approximately 77% of the company's common stock post-exercise, causing massive dilution for existing shareholders. The company explicitly warns that failure to approve the warrant issuance could jeopardize its ability to execute its business plan, potentially leading to liquidation or bankruptcy. These proposals highlight the company's severe financial distress, especially as it trades near its 52-week low, and underscore the urgent need for capital, albeit at a significant cost to current equity holders.